WALTHAM, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the appointment of Ralf Kuriyel to the position of Senior Vice President of Research & Development (R&D). Mr. Kuriyel was most recently Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (Pall), a global leader in the high-tech filtration, separation and purification markets, whose acquisition by Danaher Corporation was completed in August 2015. During his 11-year tenure at Pall, Mr. Kuriyel played a key role in expanding the Global Applications R&D function to include cell culture and single-use applications, process monitoring technologies, and process development services. Prior to Pall, Mr. Kuriyel held various technology and applications development management roles within the bioprocess and biopharm divisions of Millipore Corporation (Millipore), which was acquired by Merck KGaA in 2010. Mr. Kuriyel will take over from Dr. James Rusche, who is retiring at the end of this year following a distinguished 30-year career with the Company.
At Repligen, Mr. Kuriyel will lead Repligen’s development efforts and influence the strategic direction of the Company’s product portfolio as a core member of a cross-functional team. His responsibilities include overseeing the development of new and innovative products and services for applications within biomanufacturing, building on Repligen’s record of excellence in upstream filtration and downstream purification technology as well as its commitment to customization and convenience for end users.
Tony J. Hunt, President and Chief Executive Officer of Repligen said, “We’re very pleased to welcome Ralf to Repligen, where his combined 30 years of bioprocess technology development experience with Pall and Millipore compliments and builds upon the high caliber of our R&D organization. Ralf will be an important contributor as the Company continues on a path of growth and innovation based on anticipating and responding to the evolving needs of our biopharmaceutical manufacturing customers, particularly in the areas of flexible and continuous processing technologies.”
Mr. Kuriyel received his B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute, and completed coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over thirty scientific publications pertaining to bioprocessing - including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody-based therapeutics. In upstream processes, our XCell™ ATF systems and growth factors are used to accelerate and increase product yield during the cell culture stage of biologic drug manufacturing. In downstream processes, we developed and market our innovative line of OPUS® chromatography columns that we deliver pre-packed with our customers’ choice of resin for their bench-scale through clinical production-scale purification needs. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact: Sondra S. Newman Senior Director Investor Relations (781) 419-1881